Business context and reporting period
The supplied filing is GSI Group Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 2, 2016—not a Novanta Inc. filing or a standalone Q4 report. It covers a designer and manufacturer of photonics, vision technology and precision-motion products serving medical and advanced industrial OEM markets. Medical applications represented about 40% of revenue and advanced industrial about 60%. The filing also provides unaudited quarterly results, including Q4 2015.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $373.6 million | $364.7 million |
| Gross profit / margin | $157.9 million / 42.3% | $150.2 million / 41.2% |
| Operating income (loss), continuing operations | $28.9 million | $(16.8) million |
| Net income (loss) attributable to GSI Group | $35.6 million | $(24.3) million |
| Diluted EPS, continuing operations | $1.02 | $(0.49) |
| Operating cash flow, continuing operations | $33.4 million | $44.0 million |
- Reported revenue grew 2.4%; management calculated organic growth of 3.6%, after a 4.0% adverse currency effect and a 2.8% contribution from acquisitions and divestitures.
- Segment revenue and operating income (loss): Laser Products $168.3 million and $36.0 million; Vision Technologies $124.7 million and $(2.1) million; Precision Motion $80.5 million and $16.9 million.
- Cash and cash equivalents were $60.0 million at year-end, versus $51.1 million a year earlier. Gross borrowings under the senior credit facilities were $97.5 million; $105.0 million remained available on the revolving facility. The facilities mature in December 2017.
- Capital expenditures were $5.6 million. Management expected 2016 capital expenditures of approximately $6–7 million and stated it expected operating cash flows to cover operating and capital needs for at least the next 12 months.
Material changes versus the prior comparable period
- Revenue increased $8.9 million. Laser Products revenue fell 5.3%, principally reflecting the JK Lasers sale; Vision Technologies rose 2.1%; Precision Motion increased 24.3%, with acquisition and optical-encoder growth contributing.
- Gross margin improved 1.1 percentage points to 42.3%. Operating income improved substantially, but comparison with 2014 is affected by the prior-year $41.4 million non-cash impairment of NDS goodwill and intangible assets.
- 2015 net income included a $19.6 million pre-tax gain on the JK Lasers divestiture. Accordingly, reported earnings include a material disposal gain and should not be read as solely recurring operating performance.
- Operating cash flow declined $10.6 million, to $33.4 million; management cited working-capital effects, including higher days sales outstanding and inventory, and lower days payable outstanding.
- Year-end backlog rose to approximately $96.8 million from $82.1 million, but management cautioned that orders may be canceled or rescheduled and backlog is not a reliable revenue indicator.
Outlook, management commentary, risks and unusual items
- No specific 2016 revenue or earnings guidance is provided. Management’s stated priorities include profitable growth, product development, medical-market expansion, acquisitions and operational efficiencies.
- A restructuring program initiated in 2015 targeted $4.5–5.5 million in annualized savings when fully executed, with expected cash charges of $4.5–5.5 million and completion anticipated in Q2 2016. Costs of $3.1 million were recorded in 2015 for this program.
- In January 2016, the Company decided to discontinue its Dome-branded radiology products, which generated approximately $9 million of 2015 revenue.
- 2015 acquisitions included Applimotion, Lincoln Laser and Skyetek. Contingent consideration for acquisitions was recorded at an estimated fair value of $3.9 million; potential payments across acquisitions with open contingency periods could reach $10.3 million.
- Key risks include cyclical OEM and industrial capital spending, customer order timing and cancellations, foreign-exchange movements, dependence on some limited or single-source suppliers, product and regulatory requirements, acquisition integration and intangible-asset impairment. Vision Technologies remained loss-making and had been affected by lower visualization demand and customer qualification cycles.
- Variable-rate debt exposes the Company to interest-rate risk: a 100-basis-point increase was estimated to raise annual pre-tax interest expense by about $1.0 million. A hypothetical 10% foreign-currency depreciation was estimated to reduce equity by $11.0 million.
- The U.K. defined-benefit pension plan was underfunded by $3.5 million at year-end; expected contributions were about $1.0 million in 2016, increasing 2.9% annually thereafter. The Company said ordinary-course legal claims were not expected to have a material adverse effect, while noting no assurance of outcome.
- The independent auditor gave an unqualified opinion and concluded internal control over financial reporting was effective as of year-end. The filing reports no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer and period: the source is GSI Group Inc.’s FY 2015 10-K, despite the request metadata naming NOVANTA INC and “2015 Q4.”
- Separate recurring operating performance from the $19.6 million JK Lasers gain and consider the 2014 NDS impairment when comparing earnings.
- Track Vision Technologies performance, especially visualization sales, operating profitability and the effect of the radiology product discontinuation.
- Monitor working-capital conversion and operating cash flow, alongside acquisition-related cash needs and restructuring savings and charges.
- Review the December 2017 debt maturity, covenant headroom, revolver availability, contingent acquisition payments and U.K. pension funding obligations.